Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

real-time surveillance

- PMLiVE

South Africa releases first real-world evidence for Omicron

Briefing members of the UK parliament, the head of South Africa's Medical Association, Dr Angelique Coetzee, said the risk of severe COVID-19 was 29% lower with Omicron than Delta

- PMLiVE

UK supercharges booster programme over Omicron

The UK is to offer all vaccinated adults a COVID-19 booster to counter a ‘tidal wave of Omicron’ this winter, as evidence mounts of lower immunity from vaccines

- PMLiVE

FDA approves first pre-exposure prophylactic against COVID-19

AstraZeneca’s (AZ) Evushield offers long-acting protection against COVID-19 in people who are either unable to receive or mount an insufficient response to a vaccine

Amplifying Data Science Tools for End-to-End eClinical Solutions

Andreas Weber, Group CEO, EvidentIQ, discusses hybrid vs. fully decentralized trials, the use of real-world evidence (RWE) in clinical trials, and how an end-to-end eClinical solution can help meet increasing...

Impetus Digital

- PMLiVE

Omicron rise prompts tougher measures in England

The Omicron variant is spreading so rapidly in the UK that government experts predict 1,000-2,000 hospitalisations per day, prompting stricter control measures in England

- PMLiVE

Pfizer/BioNTech promote booster against Omicron

Preliminary laboratory studies suggest three doses of the Pfizer/BioNTech vaccine neutralises Omicron to the same extent as two doses neutralise the original, ‘wild-type’ SARS-CoV-2

- PMLiVE

Roche’s Actemra approved for severe COVID-19 in Europe

The monoclonal antibody previously used to treat inflammatory conditions such as rheumatoid arthritis is already being used in the US and Australia

- PMLiVE

Mix-and-match COVID-19 vaccines may be more effective

A small study shows a booster shot of J&J’s vaccine six months after a primary course of the Pfizer/BioNTech vaccine may offer more protection

- PMLiVE

Lilly’s combination antibody expanded to children under 12

The FDA has expanded the emergency use for bamlanivimab with etesevimab for the treatment of and post-exposure prophylaxis against COVID-19 in high-risk children aged under 12

- PMLiVE

MHRA approves second COVID-19 antibody treatment

Preclinical data for GSK and Vir’s Xevudy suggests it retains activity against Omicron and all other variants of concern

- PMLiVE

Annual COVID-19 jabs likely, says Pfizer head

Pfizer CEO predicts annual jabs will be needed to maintain a ‘very high level of protection’ against COVID-19 and emphasises the need to vaccinate children

Gamifying Surgical Training to Improve Patient Outcomes

Dr. Justin Barad, CEO and Founder of Osso VR, explores how VR and gamification are revolutionizing surgical training by providing accurate quantitative assessments and analytics before performing on a patient....

Impetus Digital

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links